WO2008141511A8 - ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION - Google Patents

ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION Download PDF

Info

Publication number
WO2008141511A8
WO2008141511A8 PCT/CN2007/070044 CN2007070044W WO2008141511A8 WO 2008141511 A8 WO2008141511 A8 WO 2008141511A8 CN 2007070044 W CN2007070044 W CN 2007070044W WO 2008141511 A8 WO2008141511 A8 WO 2008141511A8
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα
antibody
human anti
human
monoclonal antibody
Prior art date
Application number
PCT/CN2007/070044
Other languages
English (en)
Chinese (zh)
Other versions
WO2008141511A1 (fr
Inventor
Qingfa Liu
Original Assignee
Human Antibodomics Shanghai In
Qingfa Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Antibodomics Shanghai In, Qingfa Liu filed Critical Human Antibodomics Shanghai In
Priority to PCT/CN2007/070044 priority Critical patent/WO2008141511A1/fr
Publication of WO2008141511A1 publication Critical patent/WO2008141511A1/fr
Publication of WO2008141511A8 publication Critical patent/WO2008141511A8/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une protéine qui se lie spécifiquement au TNFα humain (facteur de nécrose tumorale α), c.-à-d. un anticorps monoclonal humain anti-TNFα dérivé de cellules B humaines. Les chaînes légère et lourde de l'anticorps présentent respectivement les séquences d'acides aminés présentées dans SEQ ID NO : 3 et SEQ ID NO : 4. L'invention concerne également les séquences encodées de l'anticorps humain anti-TNFα, son anticorps Fab et l'anticorps Fab pégylé. La présente invention concerne également les utilisations des anticorps pour la préparation d'un médicament pour le traitement de l'inflammation associée avec TNFα.
PCT/CN2007/070044 2007-05-22 2007-05-22 ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION WO2008141511A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070044 WO2008141511A1 (fr) 2007-05-22 2007-05-22 ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070044 WO2008141511A1 (fr) 2007-05-22 2007-05-22 ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION

Publications (2)

Publication Number Publication Date
WO2008141511A1 WO2008141511A1 (fr) 2008-11-27
WO2008141511A8 true WO2008141511A8 (fr) 2009-07-09

Family

ID=40031397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070044 WO2008141511A1 (fr) 2007-05-22 2007-05-22 ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION

Country Status (1)

Country Link
WO (1) WO2008141511A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105446A1 (fr) * 2009-03-20 2010-09-23 上海宏源生物技术有限公司 Anticorps monoclonal anti-facteur de nécrose tumorale alpha humain et son utilisation
CN102167741B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150043568A (ko) * 2002-07-19 2015-04-22 애브비 바이오테크놀로지 리미티드 TNFα 관련 질환의 치료
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体,其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
EP1831257B9 (fr) * 2004-12-29 2011-05-04 Yuhan Corporation Anticorps humanise specifique pour le facteur alpha de la necrose tumorale

Also Published As

Publication number Publication date
WO2008141511A1 (fr) 2008-11-27

Similar Documents

Publication Publication Date Title
PH12020551978A1 (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
WO2006068975A3 (fr) Proteines de liaison specifiques de la matriptase humaine
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2008017828A3 (fr) Anticorps
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
EP1578799B8 (fr) Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisations
TW200635945A (en) Antibodies against IL-13 receptor alpha 1 and uses thereof
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
WO2006087637A3 (fr) Anticorps
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
TW200745164A (en) Gene recombination antibodies composition
NZ595224A (en) Specific binding proteins and uses thereof
GEP20146050B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP2014518615A5 (fr)
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
RS52484B (en) CD40 ANTIBODIES
NZ703653A (en) Anti-fap antibodies and methods of use
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
EP2163562A3 (fr) Anticorps se liant à IL-1 beta et fragments de ceux-ci
NZ599193A (en) Siglec 15 antibodies in treating bone loss-related disease
NZ594682A (en) Fully human antibodies specific to cadm1
NZ595792A (en) Antibodies specific to cadherin-17

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07721667

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07721667

Country of ref document: EP

Kind code of ref document: A1